Loading…
Harrow, Inc. is projected to rise to $41.16 by 2027, a +20% move from its current price of $34.43. HROW is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $33.44 | $34.44 | $35.47 | +0.03% |
| May 30 | $33.05 | $34.45 | $35.91 | +0.06% |
| May 31 | $32.75 | $34.46 | $36.26 | +0.08% |
| Jun 1 | $32.50 | $34.47 | $36.56 | +0.11% |
| Jun 2 | $32.28 | $34.48 | $36.82 | +0.14% |
| Jun 3 | $32.09 | $34.49 | $37.06 | +0.17% |
| Jun 4 | $31.91 | $34.50 | $37.29 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $31.91 | $34.50 | $37.29 | +0.20% |
| Week 2 | $30.96 | $34.56 | $38.59 | +0.39% |
| Week 3 | $30.26 | $34.63 | $39.63 | +0.59% |
| Week 4 | $29.70 | $34.70 | $40.54 | +0.78% |
| Week 5 | $29.21 | $34.77 | $41.38 | +0.98% |
| Week 6 | $28.79 | $34.83 | $42.15 | +1.18% |
| Week 7 | $28.41 | $34.90 | $42.88 | +1.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Harrow, Inc. is a Healthcare company focused on eyecare pharmaceuticals in the United States. It engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products, operating through Branded and ImprimisRx segments.
The company offers ImprimisRx, an ophthalmology-focused compounded medications, and a broad portfolio that includes IHEEZO, IOPIDINE, VEVYE, ZERVIATE, BYQLOVI, MAXITROL, ILEVRO, NEVANAC, BYOOVIZ, OPUVIZ, MAXIDEX, FLAREX, TRIESENCE, NATACYN, TOBRADEX ST, VERKAZIA, FRESHKOTE preservative free (PF) is a lubricant eye drop, and other ophthalmic products. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc.
in September 2023.
Harrow was founded in 1998 and is headquartered in Nashville, Tennessee. It operates in the Healthcare category and continues to expand its ophthalmic product offerings across its Branded and ImprimisRx segments.
Harrow, Inc. trades under the symbol HROW. It currently shows a price of $33.00 and a market capitalization of $1.23B, with a rank of 2377.
The near-term technical picture is framed by a 30-day range from $26.99 to $40.34 and a neutral sentiment, with RSI14 at 40. The stock sits near a middle ground between near-term support and resistance levels, suggesting a balanced outlook in the immediate term.
Looking further ahead, the forecast envisions a rising trajectory: 2026 avg $33.00, 2027 avg $39.21, 2028 avg $53.67, 2029 avg $65.62, 2030 avg $71.35, 2040 avg $162.45, and 2050 avg $391.54 with max values climbing to $106.56 in 2030 and as high as $755.95 by 2050. The ROI figures reflect a long-run upside, up to 1086.5% by 2050.
A major floor 34.6% below — a decisive break under it would weaken the trend.
The nearest floor, 15.7% below — buyers have tended to step in here.
The nearest ceiling, 20.5% above — a clean break opens room to run.
A major ceiling 57.4% above — clearing it would confirm fresh momentum.
Key HROW support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HROW market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.08 | Buy | $33.38 | Buy |
| MA 10 | $31.89 | Buy | $33.34 | Buy |
| MA 20 | $35.29 | Sell | $34.49 | Sell |
| MA 50 | $36.26 | Sell | $36.86 | Sell |
| MA 100 | $41.14 | Sell | $38.88 | Sell |
| MA 200 | $41.33 | Sell | $39.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.10 | Neutral |
| Stoch RSI (14) | 93.90 | Sell |
| CCI (20) | -14.30 | Neutral |
| Williams %R (14) | -46.11 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | -9.94 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 53.89 | Neutral |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -3.81 | Sell |
| Ultimate (7,14,28) | 65.14 | Neutral |
| Momentum (10) | 5.40 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 34.47 | Sell |
| ADX (14) | 21.14 | Sell |
| ATR (14) | 0.98 | Info |
The 30-day technical picture is NEUTRAL, with the RSI14 at 40 and price action hovering around the mid-30s. Near-term momentum appears balanced, not signaling a strong directional swing.
Key near-term levels show a support around $29.03 and resistance near $41.50. The 30-day price range spans from $26.99 to $40.34, indicating a relatively wide swing within the near term. The stock also carries an annualized volatility of 60, underscoring sizable potential moves over shorter periods.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $29.03 | $34.43 | $50.43 | 0% | Neutral | |
| $32.40 | $41.16 | $55.54 | +20% | Neutral | |
| $42.86 | $56.08 | $78.60 | +63% | Bullish | |
| $51.41 | $68.94 | $99.58 | +100% | Bullish | |
| $54.71 | $75.01 | $111.12 | +118% | Bullish | |
| $60.55 | $84.70 | $128.29 | +146% | Bullish | |
| $58.82 | $83.84 | $129.54 | +144% | Bullish | |
| $63.27 | $91.79 | $144.41 | +167% | Bullish | |
| $75.81 | $111.86 | $178.92 | +225% | Bullish | |
| $84.47 | $126.68 | $205.77 | +268% | Bullish | |
| $107.68 | $173.84 | $301.21 | +405% | Bullish | |
| $230.23 | $422.64 | $804.48 | +11.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $29.03 | $34.43 | $40.28 | +0.00% |
| June 2026 | $28.73 | $33.80 | $40.75 | -1.83% |
| July 2026 | $29.75 | $35.32 | $43.19 | +4.48% |
| August 2026 | $30.42 | $36.37 | $44.98 | +2.98% |
| September 2026 | $30.17 | $36.28 | $45.28 | -0.24% |
| October 2026 | $31.08 | $37.58 | $47.28 | +3.58% |
| November 2026 | $32.55 | $39.55 | $50.12 | +5.24% |
| December 2026 | $32.39 | $39.53 | $50.43 | -0.04% |
Click any year to see its month-by-month HROW forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Harrow, Inc.'s 2026 outlook centres on $34.43, within a $29.03 to $50.43 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, HROW could reach as high as $55.54, with a base case around $41.16 and support toward $32.40 — roughly +20% from $34.43. Price action looks broadly range-bound.
Expect HROW to range from $42.86 to $78.60 through 2028. The $56.08 average target implies a +63% move from current prices. That is up +36% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The HROW price prediction for 2029 points to an average of $68.94 (low $51.41, high $99.58) — a potential gain of +100% on today's $34.43. Momentum favours further upside here.
In 2030, HROW is projected to trade between $54.71 and $111.12, averaging $75.01 — a potential gain of +118% from today's $34.43. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Harrow, Inc.'s 2031 outlook centres on $84.70, within a $60.55 to $128.29 range. That is up +13% on the projected 2030 average. That marks a +146% change versus current levels. Momentum favours further upside here.
By 2032, HROW could reach as high as $129.54, with a base case around $83.84 and support toward $58.82 — roughly +144% from $34.43. Buyers look set to stay in control over this stretch.
Expect HROW to range from $63.27 to $144.41 through 2033. The $91.79 average target implies a +167% move from current prices. That is up +9% on the projected 2032 average. Momentum favours further upside here.
The HROW price prediction for 2034 points to an average of $111.86 (low $75.81, high $178.92) — a potential gain of +225% on today's $34.43. Buyers look set to stay in control over this stretch.
In 2035, HROW is projected to trade between $84.47 and $205.77, averaging $126.68 — a potential gain of +268% from today's $34.43. That is up +13% on the projected 2034 average. Momentum favours further upside here.
Harrow, Inc.'s 2040 outlook centres on $173.84, within a $107.68 to $301.21 range. That is up +37% on the projected 2035 average. That marks a +405% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, HROW could reach as high as $804.48, with a base case around $422.64 and support toward $230.23 — roughly +11.3x from $34.43. Momentum favours further upside here.
Investing $1,000 in HROW today (≈ 29.044438 HROW) could be worth
$12,275.48
+$11,275.48 (+1128%) by 2050 · US Dollar
Based on the average projected HROW price of $422.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HROWwould be worth at today's price.
$1,000 invested in HROW on May 27, 2025 (≈ 37.979491 HROW) would be worth
$1,307.63
+$307.63 (+30.8%) today · 1.31× · US Dollar
Based on a HROW entry price of $26.33 vs. today's $34.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.86 | $1,115.68 | +11.6% |
| 1 month ago | $41.41 | $831.44 | -16.9% |
| 3 months ago | $53.99 | $637.71 | -36.2% |
| 6 months ago | $41.78 | $824.08 | -17.6% |
| 1 year ago | $26.33 | $1,307.63 | +30.8% |
| All time (5.0y) ago | $9.59 | $3,590.2 | +259.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HROW forecast.
Our base-case forecast reaches $69.00 around 2030.
Implied market cap at $69.00: $2.57B
The multi-year forecast points to a bullish path, with the average price rising meaningfully from 2026 through 2050. The 2027 avg is $39.21 and the 2028 avg is $53.67, followed by 2029 avg $65.62 and 2030 avg $71.35, then continuing higher to 2040 avg $162.45 and 2050 avg $391.54. The corresponding max values show substantial upside, with 2030 max $106.56, 2031 max $122.78, 2032 max $122.60, 2033 max $137.47, 2034 max $170.42, 2035 max $194.08, 2040 max $284.91, and 2050 max $755.95.
Across the horizon, ROI figures rise from 0 in 2026 to 18.8 in 2027, then to 62.6 (2028), 98.8 (2029), 116.2 (2030), 143.5 (2031), 138.2 (2032), 162.2 (2033), 219.6 (2034), 258.3 (2035), 392.3 (2040), and 1086.5 by 2050.
These are estimates of price paths and returns, not guarantees, and actual results will depend on market conditions and company performance.
Tap a question to reveal the answer.
2030 avg $71.35, min $51.66, max $106.56, ROI 116.2.
The multi-year outlook is bullish, with rising averages from 2026 to 2050 (e.g., 2027 avg $39.21, 2050 avg $391.54) and a max of $755.95 by 2050, with ROI up to 1086.5. These are estimates, not guarantees, and not financial advice.
Yes. The forecast shows a 2030 max of $106.56 and a 2031 max of $122.78, with higher tops in later years (2034 max $170.42, 2035 max $194.08, and 2050 max $755.95).
Current price $33.00; market cap $1.23B.
30-day range low $26.99 and high $40.34.
Harrow, Inc. Community Discussion
0Share your Harrow, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.